A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery of COVID-19 patients and reduced mortality. On average, it took eight days to recover for patients who received asunercept, a biotherapeutic FasL inhibitor, compared to 13 days in the control group.
This article was originally published on MedicalXpress.com